SRX3207

发表于由

上海金畔生物科技有限公司为生命科学和医药研发人员提供生物活性分子抑制剂、激动剂、特异性抑制剂、化合物库、重组蛋白，专注于信号通路和疾病研究领域。

SRX3207  纯度: 98.92%

SRX3207 是具有口服活性的、首创的 Syk/PI3K 双抑制剂，其对 Syk 和 PI3Kα 的 IC50 值分别为 10.7 nM 和 861 nM。SRX3207 缓解抗肿瘤免疫抑制。

SRX3207

SRX3207 Chemical Structure

CAS No. : 2254693-15-5

规格 价格 是否有货 数量
5 mg ￥4000 In-stock
10 mg ￥6800 In-stock
25 mg ￥13500 In-stock
50 mg ￥22000 In-stock
100 mg ￥34000 In-stock
200 mg   询价  
500 mg   询价  

* Please select Quantity before adding items.

SRX3207 相关产品

•相关化合物库:

  • Bioactive Compound Library Plus
  • Kinase Inhibitor Library
  • PI3K/Akt/mTOR Compound Library
  • Protein Tyrosine Kinase Compound Library
  • Stem Cell Signaling Compound Library
  • Anti-Cancer Compound Library
  • Autophagy Compound Library
  • Anti-Aging Compound Library
  • Differentiation Inducing Compound Library
  • Oxygen Sensing Compound Library
  • Glycolysis Compound Library
  • Cytoskeleton Compound Library
  • Anti-Breast Cancer Compound Library
  • Anti-Lung Cancer Compound Library
  • Anti-Pancreatic Cancer Compound Library
  • Anti-Blood Cancer Compound Library
  • Anti-Cancer Metabolism Compound Library
  • Angiogenesis Related Compound Library
  • Glucose Metabolism Compound Library
  • Anti-Liver Cancer Compound Library
  • Anti-Colorectal Cancer Compound Library

生物活性

SRX3207 is an orally active and first-in-class dual Syk/PI3K inhibitor, with IC50 values of 10.7 nM and 861 nM for Syk and PI3Kα, respectively. SRX3207 relieves tumor immunosuppression[1][2].

IC50 & Target[2]

Syk

10.7 nM (IC50)

PI3Kα

861 nM (IC50)

PI3Kδ

1280 nM (IC50)

PI3Kγ

11100 nM (IC50)

Zap70

1300 nM (IC50)

体外研究
(In Vitro)

SRX3207 (10 μmol/L) is able to block p-AKT at concentration[1].
SRX3207 has sufficient solubility in water (43 μmol/L)[1].

上海金畔生物科技有限公司 has not independently confirmed the accuracy of these methods. They are for reference only.
体内研究
(In Vivo)

SRX3207 (10 mg/kg, orally) increases antitumor immune response[1].

上海金畔生物科技有限公司 has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model: LLC or B16 or B16-OVA or CT26 (1 × 105) cells were injected subcutaneously into syngeneic mice[1].
Dosage: 10 mg/kg.
Administration: Orally, starting from day 10 when tumors reached 100 mm3 until tumors were harvested on day 21.
Result: Blocked phosphorylation of Syk at 348 site and Y525/526 site.
Blocked immunosuppressive MΦ polarization.
Blocked tumor growth and increased survival effectively.

分子量

555.65

Formula

C29H29N7O3S
CAS 号

2254693-15-5
运输条件

Room temperature in continental US; may vary elsewhere.
储存方式
Powder -20°C 3 years
4°C 2 years
In solvent -80°C 6 months
-20°C 1 month
溶解性数据
In Vitro: 

DMSO : 5 mg/mL (9.00 mM; Need ultrasonic)

配制储备液
浓度 溶剂体积 质量 1 mg 5 mg 10 mg
1 mM 1.7997 mL 8.9985 mL 17.9969 mL
5 mM 0.3599 mL 1.7997 mL 3.5994 mL
10 mM — — —

*

请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。
储备液的保存方式和期限：-80°C, 6 months; -20°C, 1 month。-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。
参考文献

  • [1]. Shweta Joshi, et al. Macrophage Syk–PI3Kγ Inhibits Antitumor Immunity: SRX3207, a Novel Dual Syk–PI3K Inhibitory Chemotype Relieves Tumor Immunosuppression. Molecular Cancer Therapeutics. 2020.

    [2]. Shweta Joshi, et al. Macrophage Syk-PI3Kγ Inhibits Antitumor Immunity: SRX3207, a Novel Dual Syk-PI3K Inhibitory Chemotype Relieves Tumor Immunosuppression. Mol Cancer Ther. 2020 Mar;19(3):755-764.

所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务